ArticleJournal of inflammation research2025
DL-Tryptophan Alleviates Sepsis-Related Acute Liver Injury via AhR Activation.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This research sought to elucidate the extent to which DL-tryptophan may confer protection against sepsis-induced acute liver damage (SALI) and to investigate the underlying mechanisms, particularly emphasizing aryl hydrocarbon receptor (AhR) activation. Methods: Cecal ligation and puncture (CLP) was utilized to create a murine sepsis model. Liver inflammatory factor levels were quantified via real-time PCR, and liver damage was measured by measuring AST and ALT levels. H&E staining was utilized to evaluate histological alterations, whereas macrophage responses were examined using F4/80+ labeling. TUNEL labeling was utilized to assess hepatocyte apoptosis. The interactions between DL-tryptophan and AhR were analyzed via molecular docking. Western blotting was utilized to verify AhR expression, and its function was subsequently investigated using the AhR inhibitor CH223191. Results: DL-tryptophan markedly reduced the expression of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and liver damage markers (AST, ALT) in CLP-induced sepsis. Histological study indicated that DL-tryptophan administration mitigated the deterioration of liver lobular architecture, edema, and inflammatory cell infiltration. Moreover, DL-tryptophan decreased macrophage infiltration and hepatocyte apoptosis. Molecular docking experiments revealed multiple interactions via which DL-tryptophan associates with AhR. The activation of AhR induced by DL-tryptophan was validated by an elevation in AhR expression, which was then reversed by CH223191, resulting in the reinstatement of pro-inflammatory cytokine production and liver damage. Discussion: DL-tryptophan may confer protection against SALI by activating AhR, thereby modulating the inflammatory response and mitigating liver damage. These findings emphasize DL-tryptophan as a prospective therapeutic agent for managing SALI and illustrate the critical role of AhR in organ preservation during septicemic circumstances. Further study is essential to elucidate the signaling pathways downstream of this action and to assess the clinical efficacy of DL-tryptophan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.